Q. As a part of Danaher Corporation, a leader in the global medical industry equipment sector, IDBS is well-known for providing data management solutions for the entire process of biopharma development and production. This is your first time participating in BIOPLUS-INTERPHEX KOREA 2024 (BIX 2024). Could you share your reasons for participating and which customers you're looking forward to meeting at BIX 2024? What are your expectations from participating in BIX 2024?

A. As a digital partner for global leading bio pharmaceutical companies, IDBS provides the IDBS Polar and PIMS (Process Information Management System) platforms for the entire value chain, from the research stage—the beginning of biopharma development—to production. These platforms enable the optimization of development processes based on data consistency management, facilitating faster product launches.

We are very pleased to participate in BIX 2024 for the first time. We look forward to meeting with many Korean Contract Development and Manufacturing Organizations (CDMOs) and biotech companies, anticipating business opportunities and collaborations.

Q. IDBS has announced that it will officially enter the Korean market this year, providing digital platforms for research and production to biopharmaceutical companies. Is there anything that would attract visitors’ attention at your exhibition booth? Are there any key products or technologies you'd like to showcase?

A. Recently, there has been continuous growth in research and production of new biopharmaceuticals using new modalities such as Antibody-Drug Conjugates (ADC), Adeno-Associated Virus (AAV), messenger RNA (mRNA), and Cell and Gene Therapy (CGT). Traditional Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebook (ELN) solutions used in R&D and production have limitations in handling these. We want to share success stories of effectively researching and producing new modalities including structurally complex, process-intensive large molecules through our digital platforms—IDBS Polar and PIMS.

Q. As a silver sponsor of BIX, you're also hosting a standalone conference session. Could you introduce the topic IDBS will be covering and its key points?

A. We aim to introduce digital platforms that accelerate biopharma development through new modalities. We will discuss the strengths of the IDBS Polar digital platform in developing biopharmaceuticals using rapidly growing large molecules compared to chemistry-based small molecules. We'll also cover how real-time data capture from hundreds of research and production facilities, from research to production, leads to data analysis and insight generation for process optimization.

Q. As a first-time participant, which program of BIX 2024 is IDBS looking forward to the most?

A. As it's our first participation in BIX 2024, we have high expectations. First, through our conference session, we aim to introduce IDBS's differentiated digital platform and share insights with many companies. We also would like to hear feedback and requirements from our Korean customers to continually evolve our high-quality digital platform.

Furthermore, we hope to establish synergistic partnership with domestic CDMOs and biotech companies. As a part of the Danaher Corporation, we would like to expand partnerships by connecting with our sister companies as well.